 Richard Tobin
Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloid-Derived Suppressor Cells | 5 | 2024 | 66 | 2.130 |
Why?
| | Melanoma | 9 | 2024 | 760 | 2.000 |
Why?
| | Histocompatibility Antigens Class II | 7 | 2025 | 367 | 1.160 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 5 | 2024 | 37 | 0.930 |
Why?
| | Skin Neoplasms | 4 | 2024 | 855 | 0.870 |
Why?
| | Anus Neoplasms | 1 | 2024 | 33 | 0.860 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 37 | 0.840 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 149 | 0.790 |
Why?
| | Tretinoin | 2 | 2023 | 123 | 0.740 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 118 | 0.740 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 156 | 0.730 |
Why?
| | Ipilimumab | 2 | 2019 | 33 | 0.630 |
Why?
| | Lymphocyte Activation | 5 | 2025 | 1142 | 0.600 |
Why?
| | Tumor Escape | 2 | 2017 | 42 | 0.560 |
Why?
| | Neoplasms | 3 | 2024 | 2671 | 0.530 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 190 | 0.500 |
Why?
| | B-Lymphocytes | 5 | 2025 | 847 | 0.470 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1692 | 0.410 |
Why?
| | Brain Injuries, Traumatic | 3 | 2024 | 360 | 0.400 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 417 | 0.400 |
Why?
| | Neurodegenerative Diseases | 1 | 2014 | 135 | 0.390 |
Why?
| | Brain Injuries | 1 | 2014 | 494 | 0.310 |
Why?
| | CD8-Positive T-Lymphocytes | 3 | 2024 | 900 | 0.300 |
Why?
| | Pre-Eclampsia | 3 | 2017 | 190 | 0.290 |
Why?
| | Spleen | 4 | 2022 | 514 | 0.290 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 74 | 0.250 |
Why?
| | Antigen Presentation | 2 | 2025 | 218 | 0.240 |
Why?
| | T-Lymphocytes | 4 | 2024 | 1996 | 0.240 |
Why?
| | Toll-Like Receptor 9 | 1 | 2025 | 32 | 0.240 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 210 | 0.230 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 17 | 0.230 |
Why?
| | Mice, Transgenic | 2 | 2024 | 2167 | 0.230 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 130 | 0.230 |
Why?
| | Dasatinib | 1 | 2024 | 54 | 0.220 |
Why?
| | Mucous Membrane | 1 | 2024 | 125 | 0.210 |
Why?
| | Interleukin-4 | 2 | 2014 | 216 | 0.200 |
Why?
| | Vagotomy | 1 | 2022 | 33 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.200 |
Why?
| | Myocarditis | 1 | 2024 | 100 | 0.200 |
Why?
| | Autophagy | 1 | 2025 | 284 | 0.200 |
Why?
| | Brain | 1 | 2014 | 2668 | 0.190 |
Why?
| | Capillary Permeability | 2 | 2013 | 145 | 0.190 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2129 | 0.190 |
Why?
| | Antigens, Neoplasm | 1 | 2024 | 319 | 0.190 |
Why?
| | Lymphocytes | 2 | 2020 | 397 | 0.180 |
Why?
| | Macrophage Migration-Inhibitory Factors | 1 | 2020 | 10 | 0.170 |
Why?
| | Animals | 19 | 2025 | 36940 | 0.170 |
Why?
| | Mice, Inbred C57BL | 8 | 2025 | 5757 | 0.170 |
Why?
| | Humans | 22 | 2024 | 137585 | 0.160 |
Why?
| | Killer Cells, Natural | 1 | 2023 | 449 | 0.160 |
Why?
| | Splenectomy | 1 | 2020 | 62 | 0.160 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 674 | 0.160 |
Why?
| | Renal Circulation | 1 | 2019 | 58 | 0.160 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 718 | 0.160 |
Why?
| | Mice | 12 | 2025 | 17787 | 0.150 |
Why?
| | Haploinsufficiency | 1 | 2019 | 56 | 0.150 |
Why?
| | Cytokines | 3 | 2016 | 2085 | 0.150 |
Why?
| | Immunotherapy | 1 | 2024 | 641 | 0.150 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 99 | 0.150 |
Why?
| | Lipopolysaccharides | 2 | 2019 | 886 | 0.150 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Monocytes | 2 | 2020 | 563 | 0.140 |
Why?
| | Inflammation | 5 | 2016 | 2837 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 233 | 0.130 |
Why?
| | Peritoneal Diseases | 1 | 2016 | 4 | 0.130 |
Why?
| | Granulocytes | 1 | 2017 | 80 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4295 | 0.130 |
Why?
| | Histamine | 1 | 2016 | 67 | 0.130 |
Why?
| | Fas Ligand Protein | 2 | 2015 | 60 | 0.130 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 215 | 0.130 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 224 | 0.130 |
Why?
| | fas Receptor | 2 | 2015 | 95 | 0.130 |
Why?
| | Pancreatic Cyst | 1 | 2017 | 60 | 0.130 |
Why?
| | Hepatic Encephalopathy | 1 | 2015 | 21 | 0.120 |
Why?
| | Homeostasis | 1 | 2019 | 621 | 0.120 |
Why?
| | Mast Cells | 1 | 2016 | 147 | 0.120 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2019 | 385 | 0.120 |
Why?
| | Microvessels | 2 | 2013 | 88 | 0.120 |
Why?
| | Caspase 3 | 2 | 2013 | 246 | 0.120 |
Why?
| | Endothelium, Vascular | 4 | 2014 | 927 | 0.110 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.110 |
Why?
| | Neuroimmunomodulation | 1 | 2014 | 65 | 0.110 |
Why?
| | Toll-Like Receptors | 2 | 2017 | 185 | 0.110 |
Why?
| | Lyme Disease | 1 | 2015 | 60 | 0.110 |
Why?
| | Signal Transduction | 5 | 2023 | 5079 | 0.110 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2015 | 220 | 0.100 |
Why?
| | Adaptive Immunity | 1 | 2014 | 165 | 0.100 |
Why?
| | Staurosporine | 1 | 2013 | 20 | 0.100 |
Why?
| | Immunity, Innate | 2 | 2020 | 828 | 0.100 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3412 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 43 | 0.100 |
Why?
| | NF-kappa B | 1 | 2016 | 691 | 0.100 |
Why?
| | Male | 12 | 2024 | 67762 | 0.100 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2012 | 48 | 0.100 |
Why?
| | Interleukin-10 | 1 | 2014 | 302 | 0.100 |
Why?
| | Immunologic Factors | 1 | 2014 | 236 | 0.090 |
Why?
| | Fetal Blood | 1 | 2014 | 327 | 0.090 |
Why?
| | Dendritic Cells | 1 | 2015 | 483 | 0.090 |
Why?
| | Blood Pressure | 2 | 2019 | 1786 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 1396 | 0.090 |
Why?
| | Shock, Hemorrhagic | 1 | 2013 | 167 | 0.090 |
Why?
| | Antihypertensive Agents | 1 | 2014 | 494 | 0.080 |
Why?
| | Apoptosis | 3 | 2015 | 2553 | 0.080 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 2 | 2024 | 41 | 0.080 |
Why?
| | Infant, Premature | 1 | 2014 | 574 | 0.080 |
Why?
| | Fetal Growth Retardation | 1 | 2014 | 565 | 0.070 |
Why?
| | Aged | 4 | 2024 | 23961 | 0.070 |
Why?
| | Inflammation Mediators | 3 | 2016 | 513 | 0.070 |
Why?
| | Rats | 4 | 2019 | 5647 | 0.070 |
Why?
| | Cells, Cultured | 4 | 2017 | 4193 | 0.060 |
Why?
| | Protein Kinase Inhibitors | 2 | 2024 | 916 | 0.060 |
Why?
| | Middle Aged | 4 | 2024 | 33479 | 0.060 |
Why?
| | Adenocarcinoma | 1 | 2012 | 940 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1325 | 0.060 |
Why?
| | Female | 8 | 2024 | 73304 | 0.060 |
Why?
| | Chromones | 1 | 2024 | 44 | 0.060 |
Why?
| | Presenilin-1 | 1 | 2024 | 31 | 0.060 |
Why?
| | Adult | 4 | 2024 | 37929 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2014 | 1178 | 0.060 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2024 | 66 | 0.050 |
Why?
| | Toll-Like Receptor 3 | 2 | 2014 | 28 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 90 | 0.050 |
Why?
| | Meninges | 1 | 2024 | 43 | 0.050 |
Why?
| | Proteinuria | 2 | 2014 | 97 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 622 | 0.050 |
Why?
| | Sirolimus | 1 | 2025 | 276 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 35 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 147 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2024 | 3015 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 98 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 171 | 0.050 |
Why?
| | Interleukin-2 | 1 | 2024 | 455 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 312 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.050 |
Why?
| | Vagus Nerve | 1 | 2022 | 86 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 336 | 0.050 |
Why?
| | Neoplasm Proteins | 1 | 2024 | 434 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 411 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2019 | 2486 | 0.040 |
Why?
| | Nerve Degeneration | 1 | 2020 | 46 | 0.040 |
Why?
| | Gestational Age | 2 | 2014 | 910 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 8 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 86 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 73 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.040 |
Why?
| | Nephrons | 1 | 2019 | 18 | 0.040 |
Why?
| | Cyclic N-Oxides | 1 | 2019 | 29 | 0.040 |
Why?
| | Lung | 1 | 2013 | 4060 | 0.040 |
Why?
| | Spin Labels | 1 | 2019 | 48 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 329 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 342 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 795 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 164 | 0.040 |
Why?
| | Astrocytes | 1 | 2020 | 210 | 0.040 |
Why?
| | Alzheimer Disease | 1 | 2024 | 560 | 0.040 |
Why?
| | Vasoconstriction | 1 | 2019 | 202 | 0.040 |
Why?
| | Pregnancy | 3 | 2017 | 6763 | 0.040 |
Why?
| | Mutation | 2 | 2019 | 3958 | 0.030 |
Why?
| | Toll-Like Receptor 4 | 1 | 2019 | 273 | 0.030 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1774 | 0.030 |
Why?
| | Cromolyn Sodium | 1 | 2016 | 11 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1502 | 0.030 |
Why?
| | Placenta | 2 | 2014 | 750 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2020 | 327 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2018 | 510 | 0.030 |
Why?
| | Mesentery | 1 | 2016 | 48 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2016 | 265 | 0.030 |
Why?
| | Cell Count | 1 | 2017 | 324 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 430 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2757 | 0.030 |
Why?
| | Lymphatic Vessels | 1 | 2016 | 64 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 452 | 0.030 |
Why?
| | Pentacyclic Triterpenes | 1 | 2015 | 15 | 0.030 |
Why?
| | Immunophenotyping | 1 | 2017 | 318 | 0.030 |
Why?
| | Triterpenes | 1 | 2015 | 21 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2018 | 872 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 460 | 0.030 |
Why?
| | Borrelia burgdorferi | 1 | 2015 | 19 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 298 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 63 | 0.030 |
Why?
| | Fetal Death | 1 | 2014 | 55 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 409 | 0.030 |
Why?
| | Interleukin-17 | 1 | 2015 | 119 | 0.030 |
Why?
| | Toll-Like Receptor 2 | 1 | 2015 | 115 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2024 | 15657 | 0.030 |
Why?
| | Antigens, Bacterial | 1 | 2015 | 127 | 0.030 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 81 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2015 | 228 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 247 | 0.030 |
Why?
| | Lipoproteins | 1 | 2015 | 168 | 0.030 |
Why?
| | CD3 Complex | 1 | 2014 | 106 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2014 | 141 | 0.030 |
Why?
| | Necrosis | 1 | 2014 | 246 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2014 | 191 | 0.030 |
Why?
| | Adherens Junctions | 1 | 2013 | 25 | 0.030 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2013 | 77 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2020 | 2475 | 0.020 |
Why?
| | Caspase Inhibitors | 1 | 2013 | 81 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2012 | 155 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2013 | 402 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1066 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2013 | 810 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 315 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2014 | 1353 | 0.020 |
Why?
| | Birth Weight | 1 | 2014 | 516 | 0.020 |
Why?
| | Colonic Neoplasms | 1 | 2012 | 258 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 657 | 0.020 |
Why?
| | Blotting, Western | 1 | 2012 | 1226 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2010 | 219 | 0.020 |
Why?
| | Cell Separation | 1 | 2010 | 318 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1793 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4149 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1738 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7635 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2012 | 801 | 0.020 |
Why?
| | Mitochondria | 1 | 2013 | 948 | 0.020 |
Why?
| | Hypertension | 1 | 2013 | 1295 | 0.010 |
Why?
| | Time Factors | 1 | 2014 | 6828 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 7604 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2012 | 2526 | 0.010 |
Why?
|
|
Tobin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|